How R-Biopharm is redefining the fight against tuberculosis with IP-10-based diagnostics.
It kills quietly, systematically and worldwide. Tuberculosis (TB) is still the most common deadly bacterial infectious disease on earth. According to the Global Tuberculosis Report 2025 published by the World Health Organization (WHO), around 10.7 million people fell ill in 2024 alone, with 1.23 million losing their lives.
TB is curable. The real problem lies elsewhere: in reliable and accessible diagnosis. This is exactly where R-Biopharm comes in with a new generation of an innovative Biomarker IP-10 for the detection of latent tuberculosis.
Global problem
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.